Eliglustat - Sanofi

Drug Profile

Eliglustat - Sanofi

Alternative Names: Cerdelga; Eliglustat; Eliglustat tartrate; Genz-112638; GZ 385660

Latest Information Update: 06 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Michigan
  • Developer Sanofi Genzyme
  • Class 2 ring heterocyclic compounds; Amides; Pyrrolidines; Small molecules
  • Mechanism of Action Glucosylceramide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gaucher's disease type I
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gaucher's disease type I
  • Phase III Gaucher's disease type III

Most Recent Events

  • 31 Jul 2018 Sanofi announces intention to submit regulatory application for Gaucher's disease type I (In children) in 2022 in EU
  • 24 Jun 2018 Biomarkers information updated
  • 11 Apr 2018 Phase-III clinical trials in Gaucher's disease type I (Combination therapy, In adolescents, In children) in Canada, Turkey (PO) after April 2018 (NCT03485677)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top